Development of therapeutic vaccines for the treatment of diseases DOI Creative Commons
Yaomei Tian, Die Hu, Yuhua Li

et al.

Molecular Biomedicine, Journal Year: 2022, Volume and Issue: 3(1)

Published: Dec. 8, 2022

Vaccines are one of the most effective medical interventions to combat newly emerging and re-emerging diseases. Prophylactic vaccines against rabies, measles, etc., have excellent effectiveness in preventing viral infection associated However, host immune response is unable inhibit virus replication or eradicate established diseases infected people. Therapeutic vaccines, expressing specific endogenous exogenous antigens, mainly induce boost cell-mediated immunity via provoking cytotoxic T cells elicit humoral activating B produce antibodies. The ultimate aim a therapeutic vaccine reshape for eradicating disease establishing lasting memory. Therefore, been developed treatment some infectious chronic noncommunicable Various technological strategies implemented development including molecular-based (peptide/protein, DNA mRNA vaccines), vector-based (bacterial vector yeast-based vaccines) cell-based (dendritic cell genetically modified as well combinatorial approaches. This review summarizes vaccine-induced describes status multiple types diseases, such those caused by HPV, HBV, HIV, HCV, SARS-CoV-2, cancer, hypertension, Alzheimer's disease, amyotrophic lateral sclerosis, diabetes, dyslipidemia, that evaluated recent preclinical clinical studies.

Language: Английский

Neoantigen: A New Breakthrough in Tumor Immunotherapy DOI Creative Commons

Zheying Zhang,

Manman Lu,

Yu Qin

et al.

Frontiers in Immunology, Journal Year: 2021, Volume and Issue: 12

Published: April 16, 2021

Cancer immunotherapy works by stimulating and strengthening the body’s anti-tumor immune response to eliminate cancer cells. Over past few decades, has shown remarkable efficacy in treatment of cancer, particularly success checkpoint blockade targeting CTLA-4, PD-1 PDL1, which led a breakthrough tumor immunotherapy. Tumor neoantigens, new approach immunotherapy, include antigens produced viruses integrated into genome mutant proteins, are abundantly expressed only cells have strong immunogenicity heterogeneity. A growing number studies highlighted relationship between neoantigens T cells’ recognition Vaccines developed against now being used clinical trials various solid tumors. In this review, we summarized latest advances classification process classification, identification synthesis tumor-specific as well their role current Finally, application prospects existing problems were discussed.

Language: Английский

Citations

224
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers DOI Creative Commons
Hao Zhang, Lin Liu, Jinbo Liu

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: March 21, 2023

Abstract In recent years, tumor immunotherapy has made significant progress. However, immunotherapy, particularly immune checkpoint inhibitors (e.g., PD-1/PD-L1 inhibitors), benefits only a tiny proportion of patients in solid cancers. The microenvironment (TME) acts role immunotherapy. Studies reported that tumor-associated macrophages (TAMs), as one the main components TME, seriously affected therapeutic effect inhibitors. this review, we analyzed TAMs from epigenetic and single-cell perspectives introduced mechanisms anti-programmed death protein 1(anti-PD-1) therapy. addition, summarized combination regimens enhance efficacy elaborated on different Eventually, clinical value by influencing was discussed. These above are beneficial to elucidate poor tumors point view explore strategies improve its objective remission rate

Language: Английский

Citations

180
Vaccine delivery systems toward lymph nodes DOI

Yingyue Ding,

Zhaoting Li, Ana Jaklenec

et al.

Advanced Drug Delivery Reviews, Journal Year: 2021, Volume and Issue: 179, P. 113914 - 113914

Published: Aug. 4, 2021

Language: Английский

Citations

125
Designing Cancer Immunotherapies That Engage T Cells and NK Cells DOI Creative Commons
Oleksandr Kyrysyuk, Kai W. Wucherpfennig

Annual Review of Immunology, Journal Year: 2022, Volume and Issue: 41(1), P. 17 - 38

Published: Nov. 29, 2022

T cells and natural killer (NK) have complementary roles in tumor immunity, dual cell NK attack thus offers opportunities to deepen the impact of immunotherapy. Recent work has also shown that play an important role recruiting dendritic tumors enhance induction CD8 responses, while IL-2 secreted by activates cells. Targeting immune evasion mechanisms from activating NKG2D receptor its MICA MICB ligands on for therapeutic intervention. Interestingly, share several inhibitory receptors can be targeted cell– cell–mediated immunity. These receptor-ligand systems include CD161-CLEC2D, TIGIT-CD155, NKG2A/CD94-HLA-E. We discuss emerging strategies based cytokines profoundly function both lymphocyte populations within tumors.

Language: Английский

Citations

113
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment DOI Creative Commons
Hailong Tian,

Jiangjun Cao,

Bowen Li

et al.

Bone Research, Journal Year: 2023, Volume and Issue: 11(1)

Published: Feb. 27, 2023

Osteosarcoma, with poor survival after metastasis, is considered the most common primary bone cancer in adolescents. Notwithstanding efforts of researchers, its five-year rate has only shown limited improvement, suggesting that existing therapeutic strategies are insufficient to meet clinical needs. Notably, immunotherapy certain advantages over traditional tumor treatments inhibiting metastasis. Therefore, managing immune microenvironment osteosarcoma can provide novel and valuable insight into multifaceted mechanisms underlying heterogeneity progression disease. Additionally, given advances nanomedicine, there exist many advanced nanoplatforms for enhanced satisfactory physiochemical characteristics. Here, we review classification, characteristics, functions key components osteosarcoma. This also emphasizes application, progress, prospects discusses several nanomedicine-based options enhance efficiency treatment. Furthermore, examine disadvantages standard present future perspectives immunotherapy.

Language: Английский

Citations

107
Hot and cold tumors: Immunological features and the therapeutic strategies DOI Creative Commons
Lianjie Wang, Hui Geng, Yujie Liu

et al.

MedComm, Journal Year: 2023, Volume and Issue: 4(5)

Published: Aug. 26, 2023

Abstract The “hotness” or “coldness” of the tumors are determined by information cancer cells themselves, tumor immune characteristics, microenvironment, and signaling mechanisms, which key factors affecting patients’ clinical efficacy. switch mechanism its corresponding pathological characteristics treatment strategies frontier hot spot treatment. How to distinguish effectively clarify causes, microenvironment state, very important for response efficacy treatments. Starting from concept cold tumor, this review systematically summarized molecular influencing factors, therapeutic “hot tumors,” analyzed immunophenotypes, pathways, markers that contribute tumors” in details. Different “cold based on were with drug targets proteins tumors.” Furthermore, combines different traditional medicine modern medicine, provide a basis guidance decision‐making

Language: Английский

Citations

100
The use of RNA-based treatments in the field of cancer immunotherapy DOI Creative Commons
Mohammad Chehelgerdi, Matin Chehelgerdi

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: July 7, 2023

Abstract Over the past several decades, mRNA vaccines have evolved from a theoretical concept to clinical reality. These offer advantages over traditional vaccine techniques, including their high potency, rapid development, low-cost manufacturing, and safe administration. However, until recently, concerns instability inefficient distribution of in vivo limited utility. Fortunately, recent technological advancements mostly resolved these concerns, resulting development numerous vaccination platforms for infectious diseases various types cancer. shown promising outcomes both animal models humans. This study highlights potential as alternative approach conventional techniques cancer treatment. review article aims provide thorough detailed examination vaccines, mechanisms action applications immunotherapy. Additionally, will analyze current state technology highlight future directions implementation this platform mainstream therapeutic option. The also discuss challenges limitations such stability distribution, suggest ways overcome issues. By providing comprehensive overview critical analysis contribute advancement innovative

Language: Английский

Citations

86
mRNA vaccine in cancer therapy: Current advance and future outlook DOI Creative Commons

Youhuai Li,

Mina Wang, Xueqiang Peng

et al.

Clinical and Translational Medicine, Journal Year: 2023, Volume and Issue: 13(8)

Published: Aug. 1, 2023

Abstract Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of that have shown great promise in the immunotherapy wide variety infectious diseases and cancer. In past 2 years, SARS‐CoV‐2 mRNA contributed tremendously against SARS‐CoV2, which has prompted arrival vaccine research boom, especially cancer vaccines. Compared with conventional vaccines, significant advantages, including efficient production protective immune responses, low side effects lower cost acquisition. this review, we elaborated on development as well potential biological mechanisms latest progress various tumour treatments, discussed challenges future directions for field.

Language: Английский

Citations

74
Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities DOI Creative Commons
Bolin Wang,

Jinli Pei,

Shengnan Xu

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Sept. 6, 2023

Since the successful application of messenger RNA (mRNA) vaccines in preventing COVID-19, researchers have been striving to develop mRNA for clinical use, including those exploited anti-tumor therapy. cancer emerged as a promising novel approach immunotherapy, offering high specificity, better efficacy, and fewer side effects compared traditional treatments. Multiple therapeutic are being evaluated preclinical trials, with early-phase results. However, development these faces various challenges, such tumor heterogeneity, an immunosuppressive microenvironment, practical obstacles like vaccine administration methods evaluation systems application. To address we highlight recent advances from studies trials that provide insight into identifying associated discuss potential strategies overcome them. In future, it is crucial caution diligence while promoting innovation existing barriers. A delicate balance between opportunities challenges will help guide progress this field towards its full potential.

Language: Английский

Citations

66
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome DOI Open Access

Liying Li,

Fan Zhang, Zhenyu Liu

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(1), P. 321 - 321

Published: Jan. 3, 2023

Due to the absence of hormone receptor (both estrogen receptors and progesterone receptors) along with human epidermal growth factor 2 (HER-2) amplification, treatment triple-negative breast cancer (TNBC) cannot benefit from endocrine or anti-HER-2 therapy. For a long time, chemotherapy was only systemic for TNBC. lack effective options, prognosis TNBC is extremely poor. The successful application immune checkpoint inhibitors (ICIs) launched era immunotherapy in However, current findings show modest efficacy programmed cell death- (ligand) 1 (PD-(L)1) monotherapy small proportion patients can this approach. Based on basic principles characteristics tumor microenvironment (TIME) TNBC, combination therapy expected further enhance expand beneficiary population patients. Given diversity drugs that be combined, it important select biomarkers identify target population. Moreover, side effects associated multiple should also considered.

Language: Английский

Citations

65